COMMUNIQUÉS West-GlobeNewswire

Nuvaira annonce l'achèvement de l'inscription pour le premier essai clinique à groupe témoin fictif contre la dénervation pulmonaire ciblée pour la MPOC

27/06/2017 - 15:00

MINNEAPOLIS, le 27 juin 2017 (GLOBE NEWSWIRE) - Nuvaira (anciennement connue sous le nom de Holaira), développeur de dispositifs médicaux pour traiter les maladies pulmonaires obstructives, a annoncé aujourd'hui l' [...]

Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine

27/06/2017 - 13:59

Company to host conference call at 3 pm CEST (9 am EDT) today to review study results First RSV vaccine to show immunogenicity against five distinct RSV proteins 421 subject study shows vaccine was well tolerated at all [...]

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio

27/06/2017 - 13:00

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio Series A finance raised by high quality investor syndicate for neurodegenerative diseases therapies LONDON, 27 June, 2017: Arix Bioscience plc (LSE [...]

Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017

27/06/2017 - 11:00

Heidelberg, Germany, June 27, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation [...]

Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries

27/06/2017 - 10:00

NEW YORK, June 27, 2017 (GLOBE NEWSWIRE) -- The International Society of Aesthetic Plastic Surgery (ISAPS) today released the results of their annual Global Aesthetic Survey for procedures completed in 2016, which [...]

Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA

27/06/2017 - 08:00

Company announcement, Helsinki, 27 June 2017 at 9 am Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a [...]

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

27/06/2017 - 08:00

Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical- [...]

Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union

27/06/2017 - 07:00

Sanofi and Regeneron Announce Approval of Kevzara ® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union Paris, France and Tarrytown, N.Y., June 27, 2017 - [...]

Sanofi et Regeneron annoncent l'approbation de Kevzara® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte

27/06/2017 - 07:00

Sanofi et Regeneron annoncent l'approbation de Kevzara ® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte Paris (France) et Tarrytown (New York [...]

ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA

27/06/2017 - 07:00

GHENT, Belgium, 27 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Merck & Co., Inc., Kenilworth, New Jersey, USA, known as MSD outside the United States and Canada, has started an IND- [...]

Ossur Hf : Transactions in relation to share buyback program

26/06/2017 - 18:00

Announcement from Össur hf. No. 46/2017 Reykjavík, 26 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]

Sanofi : Disclosure of trading in own shares

26/06/2017 - 18:00

Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Sanofi : Déclaration des transactions sur actions propres

26/06/2017 - 18:00

Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Scientific breakthrough on objective diagnosis of PTSD

26/06/2017 - 16:51

Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD Medibio has exclusive worldwide [...]

Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients

26/06/2017 - 15:00

DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on [...]

Novo Nordisk A/S - Share repurchase programme

26/06/2017 - 13:40

Bagsværd, Denmark, 26 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units

26/06/2017 - 09:40

Reference is made to the stock exchange notice of 14 June 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee [...]

Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL

26/06/2017 - 07:30

PRESS RELEASE Estelle® Phase IIb results on well-being and BODY weight published in LEADING peer-reviewed journal European Journal Of Contraception and Reproductive Health Care publishes article on Phase IIb results of [...]

ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

26/06/2017 - 07:00

To assess the safety and tolerability of single and multiple doses of caplacizumab in Japanese healthy volunteers To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of caplacizumab in Japanese and [...]